375 related articles for article (PubMed ID: 11889082)
61. Amiloride reduces portal hypertension in rat liver cirrhosis.
Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
[TBL] [Abstract][Full Text] [Related]
62. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
63. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
Shah V
J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
[TBL] [Abstract][Full Text] [Related]
64. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance.
Wiest R; Groszmann RJ
Semin Liver Dis; 1999; 19(4):411-26. PubMed ID: 10643626
[TBL] [Abstract][Full Text] [Related]
65. Pharmacologic management of portal hypertension.
Berzigotti A; Bosch J
Clin Liver Dis; 2014 May; 18(2):303-17. PubMed ID: 24679496
[TBL] [Abstract][Full Text] [Related]
66. Hepatic stellate cells may be potential effectors of platelet activating factor induced portal hypertension.
Chen Y; Wang CP; Lu YY; Zhou L; Su SH; Jia HJ; Feng YY; Yang YP
World J Gastroenterol; 2008 Jan; 14(2):218-23. PubMed ID: 18186558
[TBL] [Abstract][Full Text] [Related]
67. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.
Baffy G
Dig Dis Sci; 2018 Mar; 63(3):563-576. PubMed ID: 29368124
[TBL] [Abstract][Full Text] [Related]
68. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy.
Rockey DC
Gastroenterology; 2000 Jun; 118(6):1261-5. PubMed ID: 10833501
[No Abstract] [Full Text] [Related]
69. Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension.
Klein S; Hinüber C; Hittatiya K; Schierwagen R; Uschner FE; Strassburg CP; Fischer HP; Spengler U; Trebicka J
PLoS One; 2016; 11(9):e0162144. PubMed ID: 27589391
[TBL] [Abstract][Full Text] [Related]
70. Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease.
Ward NL; Haninec AL; Van Slyke P; Sled JG; Sturk C; Henkelman RM; Wanless IR; Dumont DJ
Am J Pathol; 2004 Sep; 165(3):889-99. PubMed ID: 15331413
[TBL] [Abstract][Full Text] [Related]
71. Impact of portal branch ligation on tissue regeneration, microcirculatory response and microarchitecture in portal blood-deprived and undeprived liver tissue.
Gock M; Eipel C; Linnebacher M; Klar E; Vollmar B
Microvasc Res; 2011 May; 81(3):274-80. PubMed ID: 21397614
[TBL] [Abstract][Full Text] [Related]
72. Pathophysiology of portal hypertension.
Kapoor D; Sarin SK
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S482-7. PubMed ID: 12534782
[No Abstract] [Full Text] [Related]
73. Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality?
Bosch J
J Hepatol; 2003 Dec; 39(6):1072-5. PubMed ID: 14642629
[No Abstract] [Full Text] [Related]
74. Rapid reversal of hyponatraemia in a patient with non-cirrhotic portal hypertension treated with terlipressin.
Barnes A; Cock C
Intern Med J; 2020 Feb; 50(2):254-255. PubMed ID: 32037708
[No Abstract] [Full Text] [Related]
75. 1998 Distinguished Lecture: biomechanics of the microcirculation, an integrative and therapeutic perspective.
Lee JS
Ann Biomed Eng; 2000 Jan; 28(1):1-13. PubMed ID: 10645783
[TBL] [Abstract][Full Text] [Related]
76. Pathophysiology of portal hypertension and implications for its pharmacological control.
Gibson PR; Dudley FJ
Aust N Z J Med; 1989 Apr; 19(2):172-82. PubMed ID: 2669717
[No Abstract] [Full Text] [Related]
77. MBEC special issue on microcirculation "engineering principles of vascular networks".
Pries AR; Mulvany MJ; Bakker EN
Med Biol Eng Comput; 2008 May; 46(5):407-9. PubMed ID: 18414914
[No Abstract] [Full Text] [Related]
78. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.
Parola M; Pinzani M
Mol Aspects Med; 2019 Feb; 65():37-55. PubMed ID: 30213667
[TBL] [Abstract][Full Text] [Related]
79. The burden of liver disease in Europe: a review of available epidemiological data.
Blachier M; Leleu H; Peck-Radosavljevic M; Valla DC; Roudot-Thoraval F
J Hepatol; 2013 Mar; 58(3):593-608. PubMed ID: 23419824
[TBL] [Abstract][Full Text] [Related]
80. Pathogenesis of liver fibrosis.
Hernandez-Gea V; Friedman SL
Annu Rev Pathol; 2011; 6():425-56. PubMed ID: 21073339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
